Insights™

 

Un nuovo studio di mercato, intitolato ” Previsione diagnostica al punto di cura (POC) di malattie infettive 2021-2028 “, è stato presentato su Fortune Business Insights™.

 

*** Ottieni l’ultimo rapporto di ricerca di mercato aggiornato con un rapporto di esempio gratuito

Panoramica di mercato

La malattia infettiva dimensione globale del mercato (POC) diagnostica point-of-care è atteso a prendere slancio, raggiungendo 3,96 miliardi di dollari entro il 2028, mentre esibendo un CAGR impressionante del 17,2% tra il 2021 al 2028. Nel suo rapporto intitolato ” Malattie Infettive Point-of -care (POC) Diagnostics Market, 2021-2028 “, Fortune Business Insights afferma che il mercato si è attestato a 1,12 miliardi di dollari nel 2020.

Richiesta di report campione gratuito PDF @ www.fortunebusinessinsights.com/enquiry/request-sample-pdf/infectious-disease-point-of-care-poc-diagnostics-market-104307

Impatto COVID-19

 

La pandemia di COVID-19 ha colpito moderatamente il settore farmaceutico e gli istituti di ricerca poiché questi settori sono coinvolti nello sviluppo di kit POC per la diagnosi di COVID-19. L’introduzione immediata di prodotti avanzati e kit di test pronti all’uso sta guidando la crescita del mercato. Ad esempio, nel luglio 2020, BD (Becton, Dickinson e Company) ha dichiarato che la Food and Drug Administration (FDA) statunitense ha autorizzato l’autorizzazione all’uso di emergenza (EUA) per il test diagnostico SARS-CoV-2 rapido, point-of-care, per l’uso con il suo sistema BD Veritor Plus ampiamente disponibile. Tuttavia, la domanda di molti altri kit di test, come MRSA, HIV e CDI, è diminuita a causa del completo spostamento delle aziende sui kit COVID e delle interruzioni nella catena di approvvigionamento. Pertanto, il mercato ha visto un calo dei kit di test di routine. Tuttavia, il mercato dovrebbe rivivere durante il periodo di previsione.

 

Click here to get the short-term and long-term impact of COVID-19 on this market.

Please visit:

Market Segmentation:

By technique, the market for infectious disease POC diagnostics is divided into lateral flow immunoassay, agglutination test, flow-through test, molecular diagnostics, and others.

 

  • Based on the technique, the lateral flow immunoassay segment held a share of 49.7% in 2020. This is attributable to increased research and products launch due to the COVID-19 virus. Furthermore, the availability of the test kits in decentralized settings is promoting the segment’s growth.

By disease, it is segmented into HIV, hepatitis B Virus, pneumonia/Streptococcus associated infections, respiratory syncytial virus (RSV), influenza, clostridium difficile infections (CDI), hepatitis C Virus, methicillin-resistant staphylococcus aureus (MRSA), tuberculosis, and others. By disease, COVID-19 Point-of-care diagnostics, by end-user it is segmented into hospital bedside, physician’s office lab, urgent care & retail clinics, home & self-testing, nursing homes, and Others. Finally, based on region, the market is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

What does the Report Provide?

Il rapporto di mercato per la diagnostica point-of-care delle malattie infettive fornisce un’analisi dettagliata di diversi fattori, come i fattori chiave e le restrizioni che avranno un impatto sulla crescita. Inoltre, il rapporto fornisce approfondimenti sull’analisi regionale che copre diverse regioni, contribuendo alla crescita del mercato. Include il panorama competitivo che coinvolge le aziende leader e l’adozione di strategie da parte loro per introdurre nuovi prodotti, annunciare partnership e collaborazioni che contribuiranno ulteriormente alla crescita del mercato.

Fattore di guida

Aumento della prevalenza di malattie infettive per stimolare la domanda di kit di test diagnostici POC rapidi

 

The rising prevalence of viral diseases is expected to drive infectious disease point-of-care diagnostics market growth. For instance, a report by the United Nations Program on HIV/AIDS (UNAIDS) in 2019 states that around 38 million people suffer from HIV/AIDS. Another report by the World Health Organization (WHO) stated that in the year 2018, around 10 million people were affected by tuberculosis worldwide. Thus, the rising infection of the various diseases globally has spurred the demand for POC products for the diagnosis, and subsequently, its increased demand will favor the market during the forecast period.

 

Regional Insights

 

Rising Adoption of Advanced POC Diagnostic Kit in North America to Promote Growth

 

North America is expected to hold the largest infectious disease point-of-care (POC) diagnostics market share during the forecast period.  This is attributable to the rising adoption of advanced POC diagnostics kits to detect various infectious diseases. Additionally, increasing collaboration and strategic partnerships in the region will likely promote the regional market during the forecast period. For instance, in 2019, the U.S. Department of Health and Human Services (HHS) collaborated with Inflammatix Inc. The collaborations aim to develop a rapid diagnostic test to differentiate between bacterial and viral infections such as Flu, Sepsis, and offers test results in 20-30 minutes. North America stood at USD 0.41 billion in 2020.

 

On the other hand, Europe is expected to hold the second position in the market during the forecast period. This growth is attributable to the increasing investment in R&D activities by the companies in the region during the forecast period.

 

Competitive Landscape

 

Key Players to Focus on Partnerships to Strengthen Their Positions

 

The market for infectious disease point-of-care diagnostics is consolidated by major companies striving to maintain their position by focusing on partnerships and launching new products. For instance, in July 2020, Precipio Inc. strategically partnered with ADS Biotech to develop a lateral flow immunoassay-based COVID-19 detection kit. The project has received EUA permissions but awaiting USFDA approval for distributing the kits to the physician’s lab, retail pharmacies, and direct-to-customer. Moreover, other key players adopt proactive strategies such as acquisitions, mergers, and collaborations to favor the market’s growth in the upcoming years.

 

Industry Development

  • April 2021 – Chembio Diagnostics, Inc. launched of rapid point-of-care COVID-19 /Flu A&B test. The test is an extremely fast infectious disease point-of-care diagnostics test as it provides the results within 15 minutes.

Ask for Customization @ www.fortunebusinessinsights.com/enquiry/customization/infectious-disease-point-of-care-poc-diagnostics-market-104307

List of Key Players Profiled in this Market Report

 

  • Hoffmann-La Roche Ltd (Basel, Switzerland)
  • Thermo Fisher Scientific Inc. (Massachusetts, U.S.)
  • Abbott Laboratories (Illinois, U.S)
  • Quest Diagnostics Incorporated (New Jersey, United States)
  • D. (Franklin Lakes, U.S)
  • bioMérieux SA (Marcy l’Etoile, France)
  • Cardinal Health, Inc. (Ohio, U.S)
  • Mesa Biotech (California, U.S)
  • Cepheid (California, U.S)
  • Trinity Biotech (Bray, Ireland)
  • Quidel Corporation (San Diego, U.S.)
  • Bio-Rad Laboratories Inc. (California, U.S)

 

Table Of Content:

  1. Introduction
    • Market Scope
    • Market Segmentation
    • Market Methodology
    • Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  4. Key Insights

4.1 Prevalence of Key Infectious Diseases, By Key Countries

4.2 New Product Launches

4.3 Key Industrial Developments (Mergers, Acquisitions, Partnerships, etc.)

4.4 Technological Advancements in Infectious Disease Point-of-care (POC) Diagnostics

4.5 Impact of COVID-19 on Infectious Disease Point-of-care (POC) Diagnostics Market

4.6 Overview of Initiatives for Infectious Disease Point-of-care (POC) Diagnostics in Emerging Countries

4.7 Pricing Analysis of Various Infectious Disease Point-of-care (POC) Diagnostics, By Key Companies

4.8 Analysis of Product Features of Key Infectious Disease Point-of-care (POC) Diagnostics, By Key Companies

  1. Global Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2017-2028
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Technique

5.2.1 Lateral Flow Immunoassay (LFIA)

5.2.2 Agglutination Tests

5.2.3 Flow-through Tests / Immunoconcentration Assays

5.2.4 Molecular Diagnostics

5.2.5 Others

  • Market Analysis, Insights and Forecast – By Disease
    • Human Immunodeficiency Virus (HIV)
    • Hepatitis B Virus (HBV)
    • Pneumonia / Streptococcus Associated Infections
    • Respiratory Syncytial Virus (RSV)
    • Influenza
    • Clostridium difficile infection (CDI)
    • Hepatitis C Virus (HCV)
    • Methicillin-Resistant Staphylococcus Aureus (MRSA)
    • Tuberculosis (TB)
    • Others
  • Market Analysis, Insights and Forecast – By End User
    • Hospital Bedside
    • Physician’s Office Lab
    • Urgent Care & Retail Clinics
    • Home & Self-Testing
    • Nursing Homes
    • Others
  • Market Analysis, Insights and Forecast – By Geography
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa
  1. North America Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2017-2028
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Technique

5.2.1 Lateral Flow Immunoassay (LFIA)

5.2.2 Agglutination Tests

5.2.3 Flow-through Tests / Immunoconcentration Assays

5.2.4 Molecular Diagnostics

5.2.5 Others

  • Market Analysis, Insights and Forecast – By Disease
    • Human Immunodeficiency Virus (HIV)
    • Hepatitis B Virus (HBV)
    • Pneumonia / Streptococcus Associated Infections
    • Respiratory Syncytial Virus (RSV)
    • Influenza
    • Clostridium difficile infection (CDI)
    • Hepatitis C Virus (HCV)
    • Methicillin-Resistant Staphylococcus Aureus (MRSA)
    • Tuberculosis (TB)
    • Others
  • Market Analysis, Insights and Forecast – By End User
    • Hospital Bedside
    • Physician’s Office Lab
    • Urgent Care & Retail Clinics
    • Home & Self-Testing
    • Nursing Homes
    • Others
  • Market Analysis, Insights and Forecast – By Country
    • S.
    • Canada
  1. Europe Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2017-2028
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Technique

5.2.1 Lateral Flow Immunoassay (LFIA)

5.2.2 Agglutination Tests

5.2.3 Flow-through Tests / Immunoconcentration Assays

5.2.4 Molecular Diagnostics

5.2.5 Others

  • Market Analysis, Insights and Forecast – By Disease
    • Human Immunodeficiency Virus (HIV)
    • Hepatitis B Virus (HBV)
    • Pneumonia / Streptococcus Associated Infections
    • Respiratory Syncytial Virus (RSV)
    • Influenza
    • Clostridium difficile infection (CDI)
    • Hepatitis C Virus (HCV)
    • Methicillin-Resistant Staphylococcus Aureus (MRSA)
    • Tuberculosis (TB)
    • Others
  • Market Analysis, Insights and Forecast – By End User
    • Hospital Bedside
    • Physician’s Office Lab
    • Urgent Care & Retail Clinics
    • Home & Self-Testing
    • Nursing Homes
    • Others
  • Market Analysis, Insights and Forecast – By Country/Sub-region
    • K.
    • Germany
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  1. Asia Pacific Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2017-2028
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Technique

5.2.1 Lateral Flow Immunoassay (LFIA)

5.2.2 Agglutination Tests

5.2.3 Flow-through Tests / Immunoconcentration Assays

5.2.4 Molecular Diagnostics

5.2.5 Others

  • Market Analysis, Insights and Forecast – By Disease
    • Human Immunodeficiency Virus (HIV)
    • Hepatitis B Virus (HBV)
    • Pneumonia / Streptococcus Associated Infections
    • Respiratory Syncytial Virus (RSV)
    • Influenza
    • Clostridium difficile infection (CDI)
    • Hepatitis C Virus (HCV)
    • Methicillin-Resistant Staphylococcus Aureus (MRSA)
    • Tuberculosis (TB)
    • Others
  • Market Analysis, Insights and Forecast – By End User
    • Hospital Bedside
    • Physician’s Office Lab
    • Urgent Care & Retail Clinics
    • Home & Self-Testing
    • Nursing Homes
    • Others
  • Market Analysis, Insights and Forecast – By Country/Sub-region
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  1. Latin America Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2017-2028
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Technique

5.2.1 Lateral Flow Immunoassay (LFIA)

5.2.2 Agglutination Tests

5.2.3 Flow-through Tests / Immunoconcentration Assays

5.2.4 Molecular Diagnostics

5.2.5 Others

  • Market Analysis, Insights and Forecast – By Disease
    • Human Immunodeficiency Virus (HIV)
    • Hepatitis B Virus (HBV)
    • Pneumonia / Streptococcus Associated Infections
    • Respiratory Syncytial Virus (RSV)
    • Influenza
    • Clostridium difficile infection (CDI)
    • Hepatitis C Virus (HCV)
    • Methicillin-Resistant Staphylococcus Aureus (MRSA)
    • Tuberculosis (TB)
    • Others
  • Market Analysis, Insights and Forecast – By End User
    • Hospital Bedside
    • Physician’s Office Lab
    • Urgent Care & Retail Clinics
    • Home & Self-Testing
    • Nursing Homes
    • Others
  • Market Analysis, Insights and Forecast – By Country/Sub-region
    • Brazil
    • Mexico
    • Rest of Latin America
  1. Middle East & Africa Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2017-2028
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Technique

5.2.1 Lateral Flow Immunoassay (LFIA)

5.2.2 Agglutination Tests

5.2.3 Flow-through Tests / Immunoconcentration Assays

5.2.4 Molecular Diagnostics

5.2.5 Others

  • Market Analysis, Insights and Forecast – By Disease
    • Human Immunodeficiency Virus (HIV)
    • Hepatitis B Virus (HBV)
    • Pneumonia / Streptococcus Associated Infections
    • Respiratory Syncytial Virus (RSV)
    • Influenza
    • Clostridium difficile infection (CDI)
    • Hepatitis C Virus (HCV)
    • Methicillin-Resistant Staphylococcus Aureus (MRSA)
    • Tuberculosis (TB)
    • Others
  • Market Analysis, Insights and Forecast – By End User
    • Hospital Bedside
    • Physician’s Office Lab
    • Urgent Care & Retail Clinics
    • Home & Self-Testing
    • Nursing Homes
    • Others
  • Market Analysis, Insights and Forecast – By Country/Sub-region
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  1. By Disease, COVID-19 Point of care (POC) Diagnostics Market Analysis, Insights and Forecast, 2017-2028
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Technique

5.2.1 Lateral Flow Immunoassay (LFIA)

5.2.2 Agglutination Tests

5.2.3 Flow-through Tests / Immunoconcentration Assays

5.2.4 Molecular Diagnostics

5.2.5 Others

  • Market Analysis, Insights and Forecast – By End User
    • Hospital Bedside
    • Physician’s Office Lab
    • Urgent Care & Retail Clinics
    • Home & Self-Testing
    • Nursing Homes
    • Others
  • Market Analysis, Insights and Forecast – By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa
  1. Competitive Analysis
    • Key Industry Developments
    • Global Market Share Analysis (2020)
    • Company Profiles (Overview, Product Types & Services, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
      • Hoffmann-La Roche Ltd
      • Thermo Fisher Scientific Inc.
      • Quest Diagnostics Incorporated
      • BD
      • bioMérieux SA
      • Cardinal Health, Inc.
      • Cepheid
      • Mesa Biotech
      • Trinity Biotech
      • Quidel Corporation
      • Bio-Rad Laboratories, Inc.
      • Abbott Laboratories
      • Other Prominent Players
  1. Strategic Recommendations

 

Continued. . .

Related Article @

marketresearchreportsfbi.wordpress.com/2021/11/08/autotransfusion-devices-market-by-technology-share-size-segmentation-revenue-analysis-forecast-2028/

www.theexpresswire.com/pressrelease/Dermatology-Drugs-Market-to-Reach-USD-6399-Billion-With-The-CAGR-129-During-the-Forecast-Period-2021-2028-Top-Companies-Share-Size-Growth_14683151

 

NOTE: Our team is studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. We aim to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune – 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: [email protected]

LinkedIn: www.linkedin.com/company/fortune-business-insights

Facebook: www.facebook.com/FortuneBusinessInsightsPvtLtd

Twitter: twitter.com/FBInsightPvtLtd